Document is current
Any future updates will be listed below
-
Authors
Hermans, C. https://orcid.org/0000-0001-5429-8437
Giangrande, P. L. F.
O’Mahony, B.
de Kleijn, P.
Bedford, M.
Batorova, A.
Blatný, J.
Jansone, K.
,
Astermark, J.
Crato, M.
d’Oiron, R.
Dougall, A.
Fijnvandraat, K.
Grønhaug, S.
Jiménez-Yuste, V.
Jokić, M.
Lobet, S.
Nolan, B.
Peyvandi, F.
Ryan, A.
- License Information
-
More Information
Article History
Received: 10 February 2020
Accepted: 13 August 2020
First Online: 24 August 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: PG has received consultancy and/or lecture fees from CSL Behring, Novo Nordisk, and Pfizer within the last year. CH has received consultancy and/or lecture fees from Bayer, Takeda, Roche, CSL Behring, NovoNordisk, Pfizer, SOBI, LFB, OctaPharma within the last year. AB received a speaker fee from SOBI, Roche, Shire and Octapharma within last year. MB is currently a member of the Roche/Chugai Haemophilia A Advisory Board and is in receipt of funding from Pfizer for an investigator-initiated research study. JB has received speaker’s fees and/or served as a consultant for NovoNordisk, Shire/Takeda, Sobi, LFB, Pfizer and Roche within last year. BO’M, PdK and KJ state that they have no competing interests to report.
